A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Pfizer
Genmab
Revolution Medicines, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
Tesaro, Inc.
Eli Lilly and Company
Cantargia AB
Nektar Therapeutics
Incyte Corporation
Isofol Medical AB
Gilead Sciences
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company